Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)

16. november 2026 opdateret af: Tuberculosis Research Centre, India

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

2500

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Andhra Pradesh
      • Guntur, Andhra Pradesh, Indien, 522503
        • Rekruttering
        • All India Institute of Medical Sciences(AIIMS), Mangalagiri
        • Kontakt:
    • Assam
      • Guwahati, Assam, Indien, 781101
        • Aktiv, ikke rekrutterende
        • All India Institute of Medical Sciences, Guwahati
    • Gujarat
      • Rajkot, Gujarat, Indien, 360001
        • Ikke rekrutterer endnu
        • Govt. PDU Medical College
        • Kontakt:
      • Surat, Gujarat, Indien, 395001
        • Aktiv, ikke rekrutterende
        • Govt. Medical College and NCH
    • Maharashtra
      • Mumbai, Maharashtra, Indien, 400008
        • Rekruttering
        • Grant Govt. Medical College & Sir JJ Group of Hospitals
        • Kontakt:
      • Nagpur, Maharashtra, Indien
        • Ikke rekrutterer endnu
        • All India Institute Of Medical Sciences, Nagpur
        • Kontakt:
    • Meghālaya
      • Shillong, Meghālaya, Indien, 793018
        • Rekruttering
        • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
        • Kontakt:
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110030
        • Ikke rekrutterer endnu
        • National Institute of TB and Respiratory Diseases
        • Kontakt:
    • Odisha
      • Bhubaneswar, Odisha, Indien, 751019
        • Aktiv, ikke rekrutterende
        • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
      • Bhubaneswar, Odisha, Indien, 751001
        • Aktiv, ikke rekrutterende
        • Post Graduate Institute of Medical Education & Research, Capital Hospital
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indien, 600031
        • Rekruttering
        • ICMR - National Institute for Research in Tuberculosis
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Dr PK Bhavani, MBBS., MPH., PGDBEME
        • Ledende efterforsker:
          • Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
        • Underforsker:
          • Dr R Balaji, MBBS., MD.,
    • Telangana
      • Hyderabad, Telangana, Indien, 500038
        • Rekruttering
        • Govt. General and Chest Hospital, Osmania Medical College
        • Kontakt:
    • Uttar Pradesh
      • Agra, Uttar Pradesh, Indien, 282002
        • Rekruttering
        • Sarojini Naidu Medical College
        • Kontakt:
      • Allahābād, Uttar Pradesh, Indien, 211002
        • Rekruttering
        • Moti Lal Nehru Medical College
        • Kontakt:
      • Lucknow, Uttar Pradesh, Indien, 226003
        • Rekruttering
        • King George Medical University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

14 år til 70 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
  4. If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion Criteria:

  1. Body weight less than 30 kg in adults

  2. Anti-TB treatment, >14 days for the current illness

  3. Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA

  4. Patients with serious forms of Extra-pulmonary TB

  5. HIV Patients on second line ART regimens.

  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers

  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability

  9. Patients with h/o of concomitant medications which may interfere with study drugs

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 2H R25 ZE /4 H R10 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Eksperimentel: 2 H R25 ZE/ 4 H R25 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol

Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Eksperimentel: 2 H R25 ZE L/2 H R25 E L

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg)

Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

Aktiv komparator: 2 H R10 ZE /4H R10 E

Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol

Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Tidsramme: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients with grade 3 or 4 adverse drug reactions.
Tidsramme: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Tidsramme: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Tidsramme: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Tidsramme: At 1st Month
At 1st Month
The cost effectiveness of different treatment regimens
Tidsramme: Through treatment completion, an average of 24 weeks

Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

Through treatment completion, an average of 24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
  • Ledende efterforsker: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. juni 2026

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

9. november 2026

Først indsendt, der opfyldte QC-kriterier

16. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .